{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:04:32Z","timestamp":1785809072703,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Patients with persistent or recurrent papillary and poorly differentiated thyroid cancer can be effectively treated with radioiodine, if the tumour tissue is iodine-avid. However, iodine-avidity status is often unknown at the time of initial radioiodine treatment, limiting any adaptive approach. This study aimed to clarify the relationship between pre-therapeutic iodine avidity in primary tumour tissue, initial lymph node metastases and iodine uptake in subsequent metastases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Iodine avidity was prospectively assessed pre-therapeutically in 35 patients by injection of tracer amounts of iodine-131 two days prior to surgery. Iodine concentrations in resected tissue samples were measured, enabling accurate and histologically verifiable iodine avidity data for both primary tumour and initial lymph node metastases. Iodine uptake in persistent metastatic disease was assessed by review of radiology, and treatment response was examined through journal studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of data from 35 patients, 10 had persistent disease at presentation or during follow-up (range 19\u201346 months). Four patients had non-avid persistent metastatic disease, all with low iodine avidity in their primary tumours and initial lymph node metastases. Patients with low pre-therapeutic iodine avidity did not appear to have greater risk of persistent disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The results indicate a close link between pre-therapeutically measured iodine concentrations in primary tumours with iodine avidity of any subsequent metastases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-023-03414-7","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T04:34:31Z","timestamp":1686112471000},"page":"343-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Primary tumour iodine avidity in relation to uptake in persistent metastatic disease in papillary and poorly differentiated thyroid cancer"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7496-9189","authenticated-orcid":false,"given":"Joachim N.","family":"Nilsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1141-6234","authenticated-orcid":false,"given":"Per","family":"Gryb\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-9081","authenticated-orcid":false,"given":"C. Christofer","family":"Juhlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4183-7598","authenticated-orcid":false,"given":"Christel","family":"Hedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2114-5949","authenticated-orcid":false,"given":"Catharina Ihre","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"3414_CR1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/ijc.11275","volume":"106","author":"CI Lundgren","year":"2003","unstructured":"C.I. Lundgren, P. Hall, A. Ekbom, J. Frisell, J. Zedenius, P.W. Dickman, Incidence and survival of swedish patients with differentiated thyroid cancer. Int. J. Cancer 106, 569\u2013573 (2003). https:\/\/doi.org\/10.1002\/ijc.11275","journal-title":"Int. J. Cancer"},{"key":"3414_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1089\/thy.1999.9.421","volume":"9","author":"EL Mazzaferri","year":"1999","unstructured":"E.L. Mazzaferri, An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 9, 421\u2013427 (1999). https:\/\/doi.org\/10.1089\/thy.1999.9.421","journal-title":"Thyroid"},{"key":"3414_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1\u2013133 (2016). https:\/\/doi.org\/10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"key":"3414_CR4","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli, B. Caillou, M. Ricard, J.D. Lumbroso, F. De Vathaire et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892\u20132899 (2006). https:\/\/doi.org\/10.1210\/jc.2005-2838","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3414_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.surg.2013.07.008","volume":"154","author":"RH Grogan","year":"2013","unstructured":"R.H. Grogan, S.P. Kaplan, H. Cao, R.E. Weiss, L.J. Degroot, C.A. Simon, O.M.A. Embia, P. Angelos, E.L. Kaplan, R.B. Schechter, A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery 154, 1436\u20131446 (2013). https:\/\/doi.org\/10.1016\/j.surg.2013.07.008.","journal-title":"Surgery"},{"key":"3414_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00268-018-4479-z","volume":"42","author":"Y Ito","year":"2018","unstructured":"Y. Ito, A. Miyauchi, M. Kihara, M. Fukushima, T. Higashiyama, A. Miya, Overall survival of papillary thyroid carcinoma patients: a single-institution long-term follow-up of 5897 patients. World J. Surg. 42, 615\u2013622 (2018). https:\/\/doi.org\/10.1007\/s00268-018-4479-z","journal-title":"World J. Surg."},{"key":"3414_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1210\/jc.2013-3842","volume":"99","author":"T Ibrahimpasic","year":"2014","unstructured":"T. Ibrahimpasic, R. Ghossein, D.L. Carlson, I. Nixon, F.L. Palmer, A.R. Shaha, S.G. Patel, R.M. Tuttle, J.P. Shah, I. Ganly, Outcomes in patients with poorly differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 99, 1245\u20131252 (2014). https:\/\/doi.org\/10.1210\/jc.2013-3842","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3414_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1089\/thy.2018.0509","volume":"29","author":"T Ibrahimpasic","year":"2019","unstructured":"T. Ibrahimpasic, R. Ghossein, J.P. Shah, I. Ganly, Poorly differentiated carcinoma of the thyroid gland: current status and future prospects. Thyroid 29, 311\u2013321 (2019). https:\/\/doi.org\/10.1089\/thy.2018.0509","journal-title":"Thyroid"},{"key":"3414_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jso.23967","volume":"112","author":"F-H Liu","year":"2015","unstructured":"F.-H. Liu, S.-F. Kuo, C. Hsueh, T.-C. Chao, J.-D. Lin, Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis. J. Surg. Oncol. 112, 149\u2013154 (2015). https:\/\/doi.org\/10.1002\/jso.23967","journal-title":"J. Surg. Oncol."},{"key":"3414_CR10","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00268-002-6612-1","volume":"26","author":"ID Hay","year":"2002","unstructured":"I.D. Hay, G.B. Thompson, C.S. Grant, E.J. Bergstralh, C.E. Dvorak, C.A. Gorman, M.S. Maurer, B. McIver, B.P. Mullan, A.L. Oberg et al. Papillary thyroid carcinoma managed at the mayo clinic during six decades (1940\u20131999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J. Surg. 26, 879\u2013885 (2002). https:\/\/doi.org\/10.1007\/s00268-002-6612-1","journal-title":"World J. Surg."},{"key":"3414_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1089\/thy.2014.0294","volume":"25","author":"SC Londero","year":"2015","unstructured":"S.C. Londero, A. Krogdahl, L. Bastholt, J. Overgaard, H.B. Pedersen, C.H. Hahn, J. Bentzen, S. Schytte, P. Christiansen, O. Gerke et al. Papillary thyroid carcinoma in Denmark, 1996\u20132008: outcome and evaluation of established prognostic scoring systems in a prospective national cohort. Thyroid 25, 78\u201384 (2015). https:\/\/doi.org\/10.1089\/thy.2014.0294","journal-title":"Thyroid"},{"key":"3414_CR12","doi-asserted-by":"publisher","first-page":"E829","DOI":"10.1210\/jc.2012-3933","volume":"98","author":"MM Sabra","year":"2013","unstructured":"M.M. Sabra, J.M. Dominguez, R.K. Grewal, S.M. Larson, R.A. Ghossein, R.M. Tuttle, J.A. Fagin, Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J. Clin. Endocrinol. Metab. 98, E829\u2013E836 (2013). https:\/\/doi.org\/10.1210\/jc.2012-3933","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3414_CR13","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.3390\/cancers13143627","volume":"13","author":"JN Nilsson","year":"2021","unstructured":"J.N. Nilsson, J. Siikanen, C. Hedman, C.C. Juhlin, C. Ihre Lundgren, Pre-therapeutic measurements of iodine avidity in papillary and poorly differentiated thyroid cancer reveal associations with thyroglobulin expression, histological variants and Ki-67 index. Cancers (Basel) 13, 3627 (2021). https:\/\/doi.org\/10.3390\/cancers13143627","journal-title":"Cancers (Basel)"},{"key":"3414_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.117.193706","volume":"59","author":"H H\u00e4nscheid","year":"2018","unstructured":"H. H\u00e4nscheid, C. Lapa, A.K. Buck, M. Lassmann, R.A. Werner, Dose mapping after endoradiotherapy with 177Lu-DOTATATE\/DOTATOC by a single measurement after 4 days. J. Nucl. Med. 59, 75\u201381 (2018). https:\/\/doi.org\/10.2967\/jnumed.117.193706","journal-title":"J. Nucl. Med."},{"key":"3414_CR15","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1002\/mp.12886","volume":"45","author":"MT Madsen","year":"2018","unstructured":"M.T. Madsen, Y. Menda, T.M. O\u2019Dorisio, M.S. O\u2019Dorisio, Technical note: single time point dose estimate for exponential clearance. Med. Phys. 45, 2318\u20132324 (2018). https:\/\/doi.org\/10.1002\/mp.12886","journal-title":"Med. Phys."},{"key":"3414_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Z.W. Baloch, S.L. Asa, J.A. Barletta, R.A. Ghossein, C.C. Juhlin, C.K. Jung, V.A. LiVolsi, M.G. Papotti, M. Sobrinho-Sim\u00f5es, G. Tallini et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr. Pathol. 33, 27\u201363 (2022). https:\/\/doi.org\/10.1007\/s12022-022-09707-3","journal-title":"Endocr. Pathol."},{"key":"3414_CR17","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1097\/PAS.0b013e3180309e6a","volume":"31","author":"M Volante","year":"2007","unstructured":"M. Volante, P. Collini, Y.E. Nikiforov, A. Sakamoto, K. Kakudo, R. Katoh, R.V. Lloyd, V.A. LiVolsi, M. Papotti, M. Sobrinho-Simoes et al. Poorly differentiated thyroid carcinoma: the turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am. J. Surg. Pathol. 31, 1256\u20131264 (2007). https:\/\/doi.org\/10.1097\/PAS.0b013e3180309e6a","journal-title":"Am. J. Surg. Pathol."},{"key":"3414_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"M.B. Amin, F.L. Greene, S.B. Edge, C.C. Compton, J.E. Gershenwald, R.K. Brookland, L. Meyer, D.M. Gress, D.R. Byrd, D.P. Winchester, The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging: the eighth edition ajcc cancer staging manual. CA: A Cancer J. Clin. 67, 93\u201399 (2017). https:\/\/doi.org\/10.3322\/caac.21388","journal-title":"CA: A Cancer J. Clin."},{"key":"3414_CR19","unstructured":"S. Jansson, A. Bergenfelz, J. Hennings, O. Gimm. Sk\u00f6ldk\u00f6rtelcancer, Nationellt v\u00e5rdprogram Available online: https:\/\/kunskapsbanken.cancercentrum.se\/diagnoser\/skoldkortelcancer\/ (accessed on 7 May 2023)."},{"key":"3414_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.03.012","volume":"125","author":"Y Jin","year":"2018","unstructured":"Y. Jin, D. Van Nostrand, L. Cheng, M. Liu, L. Chen, Radioiodine refractory differentiated thyroid cancer. Crit. Rev. Oncol.\/Hematol. 125, 111\u2013120 (2018). https:\/\/doi.org\/10.1016\/j.critrevonc.2018.03.012","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"3414_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1089\/thy.2018.0048","volume":"28","author":"D Van Nostrand","year":"2018","unstructured":"D. Van Nostrand, Radioiodine refractory differentiated thyroid cancer: time to update the classifications. Thyroid 28, 1083\u20131093 (2018). https:\/\/doi.org\/10.1089\/thy.2018.0048","journal-title":"Thyroid"},{"key":"3414_CR22","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2967\/jnumed.116.180240","volume":"58","author":"X Yang","year":"2017","unstructured":"X. Yang, J. Li, X. Li, Z. Liang, W. Gao, J. Liang, S. Cheng, Y. Lin, TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer. J. Nucl. Med. 58, 258\u2013265 (2017). https:\/\/doi.org\/10.2967\/jnumed.116.180240","journal-title":"J. Nucl. Med."},{"key":"3414_CR23","doi-asserted-by":"publisher","unstructured":"Z. Meng, M. Matsuse, V. Saenko, S. Yamashita, P. Ren, X. Zheng, Q. Jia, J. Tan, N. Li, W. Zheng et al. TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower 131 i uptake in metastases. IUBMB Life 2019, iub.2056, https:\/\/doi.org\/10.1002\/iub.2056.","DOI":"10.1002\/iub.2056"},{"key":"3414_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/RLU.0000000000000498","volume":"39","author":"K Yang","year":"2014","unstructured":"K. Yang, H. Wang, Z. Liang, Y. Lin, BRAFV600E mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma. Clin. Nucl. Med. 39, 5 (2014)","journal-title":"Clin. Nucl. Med."},{"key":"3414_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2967\/jnumed.119.227652","volume":"61","author":"J Liu","year":"2020","unstructured":"J. Liu, R. Liu, X. Shen, G. Zhu, B. Li, M. Xing, The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer. J. Nucl. Med 61, 177\u2013182 (2020). https:\/\/doi.org\/10.2967\/jnumed.119.227652","journal-title":"J. Nucl. Med"},{"key":"3414_CR26","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/RLU.0000000000002078","volume":"43","author":"K Nakanishi","year":"2018","unstructured":"K. Nakanishi, T. Kikumori, N. Miyajima, Y. Takano, S. Noda, D. Takeuchi, S. Iwano, Y. Kodera, Impact of patient age and histological type on radioactive iodine avidity of recurrent lesions of differentiated thyroid carcinoma. Clin. Nucl. Med. 43, 482\u2013485 (2018). https:\/\/doi.org\/10.1097\/RLU.0000000000002078","journal-title":"Clin. Nucl. Med."},{"key":"3414_CR27","doi-asserted-by":"publisher","first-page":"e3911","DOI":"10.1210\/clinem\/dgab436","volume":"106","author":"J Sim\u00f5es-Pereira","year":"2021","unstructured":"J. Sim\u00f5es-Pereira, N. Mourinho, T.C. Ferreira, E. Limbert, B.M. Cavaco, V. Leite, Avidity and outcomes of radioiodine therapy for distant metastasis of distinct types of differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 106, e3911\u2013e3922 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgab436","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3414_CR28","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/bjs.11145","volume":"106","author":"N Chereau","year":"2019","unstructured":"N. Chereau, T.O. Oyekunle, A. Zambeli-Ljepovi\u0107, H.S. Kazaure, S.A. Roman, F. Menegaux, J.A. Sosa, Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC\/UICC staging system. Br. J. Surg. 106, 889\u2013897 (2019). https:\/\/doi.org\/10.1002\/bjs.11145","journal-title":"Br. J. Surg."},{"key":"3414_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2265.2012.04343.x","volume":"77","author":"K M\u00fcssig","year":"2012","unstructured":"K. M\u00fcssig, T. Wehrmann, H. Dittmann, M. Wehrmann, B. Ueberberg, S. Schulz, R. Bares, S. Petersenn, Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas. Clin. Endocrinol. (Oxf.) 77, 139\u2013145 (2012). https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04343.x","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"3414_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000347148","volume":"2","author":"A Miyauchi","year":"2013","unstructured":"A. Miyauchi, T. Kudo, M. Hirokawa, Y. Ito, M. Kihara, T. Higashiyama, T. Yabuta, H. Masuoka, H. Shindo, K. Kobayashi et al. Ki-67 labeling index is a predictor of postoperative persistent disease and cancer growth and a prognostic indicator in papillary thyroid carcinoma. Eur. Thyroid J. 2, 57\u201364 (2013). https:\/\/doi.org\/10.1159\/000347148","journal-title":"Eur. Thyroid J."},{"key":"3414_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1089\/105072503321669866","volume":"13","author":"P Kjellman","year":"2003","unstructured":"P. Kjellman, G. Wallin, A. H\u00f6\u00f6g, G. Auer, C. Larsson, J. Zedenius, MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma. Thyroid 13, 371\u2013380 (2003). https:\/\/doi.org\/10.1089\/105072503321669866","journal-title":"Thyroid"},{"key":"3414_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fendo.2020.00082","volume":"11","author":"D Laha","year":"2020","unstructured":"D. Laha, N. Nilubol, M. Boufraqech, New therapies for advanced thyroid cancer. Front Endocrinol. (Lausanne) 11, 82 (2020). https:\/\/doi.org\/10.3389\/fendo.2020.00082","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"3414_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11864-016-0404-6","volume":"17","author":"S Narayanan","year":"2016","unstructured":"S. Narayanan, A.D. Colevas, Current standards in treatment of radioiodine refractory thyroid cancer. Curr. Treat. Options Oncol. 17, 30 (2016). https:\/\/doi.org\/10.1007\/s11864-016-0404-6","journal-title":"Curr. Treat. Options Oncol."},{"key":"3414_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.clon.2020.11.010","volume":"33","author":"M Beasley","year":"2021","unstructured":"M. Beasley, K. Garcez, Prospects for personalised treatment of patients with radioiodine-avid locally recurrent or metastatic thyroid cancer. Clin. Oncol. (R. Coll. Radio.) 33, 75\u201379 (2021). https:\/\/doi.org\/10.1016\/j.clon.2020.11.010","journal-title":"Clin. Oncol. (R. Coll. Radio.)"},{"key":"3414_CR35","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1530\/ERC-19-0491","volume":"27","author":"C Buffet","year":"2020","unstructured":"C. Buffet, J. Wassermann, F. Hecht, L. Leenhardt, C. Dupuy, L. Groussin, C. Lussey-Lepoutre, Redifferentiation of radioiodine-refractory thyroid cancers. Endocr.-Relat. Cancer 27, R113\u2013R132 (2020). https:\/\/doi.org\/10.1530\/ERC-19-0491","journal-title":"Endocr.-Relat. Cancer"},{"key":"3414_CR36","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1210\/jc.2018-01478","volume":"104","author":"LA Dunn","year":"2019","unstructured":"L.A. Dunn, E.J. Sherman, S.S. Baxi, V. Tchekmedyian, R.K. Grewal, S.M. Larson, K.S. Pentlow, S. Haque, R.M. Tuttle, M.M. Sabra et al. Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers. J. Clin. Endocrinol. Metab. 104, 1417\u20131428 (2019). https:\/\/doi.org\/10.1210\/jc.2018-01478","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3414_CR37","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1158\/1078-0432.CCR-14-2915","volume":"21","author":"SM Rothenberg","year":"2015","unstructured":"S.M. Rothenberg, D.G. McFadden, E.L. Palmer, G.H. Daniels, L.J. Wirth, Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin. Cancer Res. 21, 1028\u20131035 (2015). https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2915","journal-title":"Clin. Cancer Res."},{"key":"3414_CR38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"AL Ho","year":"2013","unstructured":"A.L. Ho, R.K. Grewal, R. Leboeuf, E.J. Sherman, D.G. Pfister, D. Deandreis, K.S. Pentlow, P.B. Zanzonico, S. Haque, S. Gavane et al. Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer. N. Engl. J. Med. 368, 623\u2013632 (2013). https:\/\/doi.org\/10.1056\/NEJMoa1209288","journal-title":"N. Engl. J. Med."},{"key":"3414_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s13139-019-00592-z","volume":"53","author":"P Kumar","year":"2019","unstructured":"P. Kumar, C. Bal, N.A. Damle, S. Ballal, S.N. Dwivedi, S. Agarwala, Lesion-wise comparison of pre-therapy and post-therapy effective half-life of iodine-131 in pediatric and young adult patients with differentiated thyroid cancer undergoing radioiodine therapy. Nucl. Med. Mol. Imaging 53, 199\u2013207 (2019). https:\/\/doi.org\/10.1007\/s13139-019-00592-z","journal-title":"Nucl. Med. Mol. Imaging"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03414-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03414-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03414-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T07:07:33Z","timestamp":1696057653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03414-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["3414"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03414-7","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"10 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the Regional Ethical Review Board in Stockholm and the Radiation Protection Committee at Karolinska University Hospital (2017\/2393-31, 2020-01222).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}